ReviewCritical care (London, England)2024
Combining proteins with n-3 PUFAs (EPA + DHA) and their inflammation pro-resolution mediators for preservation of skeletal muscle mass.
Review in Critical care (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Trial
- Current concepts on feeding the critically ill patient: a narrative review.Critical care (London, England) · 2026Review
- The Role of Omega-3 Polyunsaturated Fatty Acids on Sarcopenia and Aging Muscle.International journal of environmental research and public health · 2026Review
- Revisiting Bill Lands' Hypotheses: HUFA Balance, Immuno-Metabolic Regulation, and Conflicting Clinical Evidence.Nutrients · 2026Review
- Trends and Prospects in Inflammation Resolution in Acute Lung Injury and Acute Respiratory Distress Syndrome: A Bibliometric Quantitative and Visualization Analysis.Mediators of inflammation · 2026Article
- Comprehensive Plasma Oxylipin Profiling Reveals a Pro-Inflammatory Eicosanoid Signature and Diagnostic Biomarker Panel in Dilated Cardiomyopathy.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Muscle preservation during hospitalization: energy balance, protein intake, and habitual physical activity.Current opinion in clinical nutrition and metabolic care · 2025Review
- Effects of dietary camelina oil intake on skeletal muscle metabolism and sarcopenia in older mice.Journal of physiology and biochemistry · 2025Article
- Molecular Mechanisms Underlying Differences in Athletic Ability in Racehorses Based on Whole Transcriptome Sequencing.Biology · 2025Article
- n-3 PUFAs docosahexaenoic acid and eicosapentaenoic acid are effective natural pro-resolution ingredients for topical skin applications.International journal of cosmetic science · 2025Review
- Biofortification of potato nutrition.Journal of advanced research · 2025Review
- The research progress and potential applications ofThe British journal of nutrition · 2025Review
- From Fish Oil to Resolution: A Narrative Review on the Potential of SPM-Enriched Marine Oil for Exercise-Induced Muscle Damage Recovery.Nutrients · 2025Review
- Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia.Current nutrition reports · 2025Review
- Association between the geriatric nutritional risk index and adverse post-extubation outcomes for critically ill older adults: a retrospective study.BMC pulmonary medicine · 2025Article
- Unraveling the metabolic pathways between atherosclerosis and sarcopenia.Frontiers in endocrinology · 2025Review
- Genetically Predicted Gut Microbiota Mediate the Association Between Fatty Acids and Intrahepatic Cholestasis of Pregnancy: A Mendelian Randomization Analysis.Food science & nutrition · 2025Article
- Unveiling the Lipid Features and Valorization Potential of Atlantic Salmon (Marine drugs · 2024Article
- Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation.Molecular medicine (Cambridge, Mass.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal feeding strategy for critically ill patients is still debated, but feeding must be adapted to individual patient needs. Critically ill patients are at risk of muscle catabolism, leading to loss of muscle mass and its consequent clinical impacts. Timing of introduction of feeding and protein targets have been explored in recent trials. These suggest that "moderate" protein provision (maximum 1.2 g/kg/day) is best during the initial stages of illness. Unresolved inflammation may be a key factor in driving muscle catabolism. The omega-3 (n-3) fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are substrates for synthesis of mediators termed specialized pro-resolving mediators or SPMs that actively resolve inflammation. There is evidence from other settings that high-dose oral EPA + DHA increases muscle protein synthesis, decreases muscle protein breakdown, and maintains muscle mass. SPMs may be responsible for some of these effects, especially upon muscle protein breakdown. Given these findings, provision of EPA and DHA as part of medical nutritional therapy in critically ill patients at risk of loss of muscle mass seems to be a strategy to prevent the persistence of inflammation and the related anabolic resistance and muscle loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.